metformin and Fatty Liver, Nonalcoholic studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

Excerpt	Relevance	Reference
"This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease."	9.69	Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. ( Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S, 2023)
"To undertake a network meta-analysis to compare the relative efficacy of a dual peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonist, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin in patients with non-alcoholic fatty liver disease (NAFLD)."	9.41	PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis. ( Li, J; Wu, WH; Yan, Q; Zhang, H; Zhang, ZY; Zhao, Y, 2023)
"This is the first meta-analysis of the available literature about the efficacy of metformin exclusively in pediatric patients with non-alcoholic fatty liver disease (NAFLD)."	9.41	The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. ( Cheirakis, K; Christakopoulos, A; Fotoulaki, M; Gkiourtzis, N; Glava, A; Michou, P; Moutafi, M; Vouksinou, E, 2023)
"To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease."	9.30	Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. ( Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL, 2019)
"This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)."	9.27	Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018)
"The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)."	9.24	Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. ( Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D, 2017)
"The Cochrane Library, PubMed, Scopus, and EMBASE database was systematically searched on 12 April 2022, using the keywords metformin; non-alcoholic fatty liver disease; and children to identify similar studies."	9.22	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. ( Chen, JA; Huang, JS; Huang, ZH; Lai, JM; Lin, MH; Peng, JY; Wu, QL; Xie, ZC; Yuan, Y; Zeng, SX; Zhu, Z, 2022)
"Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD."	9.17	Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. ( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013)
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3."	9.15	Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011)
"Metformin (MET) and genistein (GEN) have a beneficial role in alleviating non-alcoholic fatty liver disease (NAFLD), but their combined effect on this disease has not yet been studied."	8.02	Combination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice. ( Bagherieh, M; Emamgholipour, S; Hashemnia, SMR; Meshkani, R; Shabani, M; Zamani-Garmsiri, F, 2021)
"The antidiabetic drug metformin has been proposed to affect non-alcoholic fatty liver disease (NAFLD) through its effects on intestinal microbiota and barrier function."	7.91	Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. ( Baumann, A; Bergheim, I; Brandt, A; Camarinha-Silva, A; Hernández-Arriaga, A; Jin, CJ; Kehm, R; Nier, A; Sánchez, V, 2019)
"To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone."	7.83	Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016)
"To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet."	7.77	[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011)
" Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study."	7.77	Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011)
"Combined treatment with pioglitazone-metformin can effectively reduce liver fat content and gamma-GT level in newly diagnosed diabetic patients with nonalcoholic fatty liver disease, and adverse events do not increase compared with the control group, showing good safety and tolerance."	7.30	Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study. ( Jianfang, F; Jianrong, L; Jie, M; Jing, X; Jingxuan, L; Kaiyan, M; Mengying, L; Qian, X; Qingzhen, H; Qiuhe, J; Taixiong, C; Wanxia, X; Wenjuan, Y; Xiling, G, 2023)
"A total of 50 patients with NAFLD and T2DM treated with metformin were randomized (1:1) to metformin plus add-on linagliptin (linagliptin group) or to an increased dose of metformin (metformin group) for 52 weeks."	7.01	Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. ( Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N, 2021)
"Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)."	6.94	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. ( Guo, W; Lin, L; Tian, W; Xu, X, 2020)
"Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide."	6.90	Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. ( Duława, J; Handzlik, G; Holecki, M; Kędzierski, L; Kozaczka, J; Kukla, M; Pawlicki, K; Wyskida, K, 2019)
"Metformin is first-line treatment of type 2 diabetes mellitus and reduces cardiovascular events in patients with insulin resistance and type 2 diabetes."	6.90	Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. ( Brøsen, K; Feddersen, S; Gormsen, LC; Grønbaek, H; Hamilton-Dutoit, SJ; Heebøll, S; Jakobsen, S; Jessen, N; Munk, OL; Pedersen, SB; Sundelin, EIO; Vendelbo, MH, 2019)
"Lobeglitazone-treated patients showed significantly decreased CAP values (313."	6.84	Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. ( Cho, YM; Jin, HY; Kim, JH; Kim, SR; Lee, BW; Lee, YH; Rhee, EJ, 2017)
"Metformin treatment was associated with a significant decrease in OPG levels in patients with NAFLD."	6.82	Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. ( Shargorodsky, M; Sofer, E, 2016)
"Bicyclol is a synthetic compound known to protect the liver against oxidation and lipid injuries."	6.79	Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. ( Ding, XD; Fan, JG; Han, Y; Ma, AL; Shi, JP; Xu, Y, 2014)
"Metformin treatment was associated with significant decrease in PWV and AI in NAFLD patients."	6.76	Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011)
" Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks."	6.76	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons for the increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels."	6.72	The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. ( Hu, H; Li, X; Meng, J; Shen, L; Shi, D; Wang, J, 2021)
"Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible."	6.72	Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. ( Chattipakorn, N; Leerapun, A; Pinyopornpanish, K, 2021)
"The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB)."	6.50	Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). ( Doycheva, I; Loomba, R, 2014)
"Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology."	6.50	Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. ( Abenavoli, L; Milic, N; Rouabhia, S, 2014)
"Metformin is an antidiabetic drug used widely in clinical practice."	6.48	Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012)
"Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world."	5.91	Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome. ( Augusto, CT; de la Paz Scribano Parada, M; Del Carmen Baez, M; Fonseca, I; Rossi, MM; Signorini, F, 2023)
"Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on liver steatosis is unclear."	5.91	Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. ( Bahramzadeh, A; Goodarzi, G; Meshkani, R; Panahi, G; Tehrani, SS, 2023)
"Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidities and mortality, and no effective drug treatment currently exists."	5.72	Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase. ( Chen, AY; Chen, YA; Lee, YC; Li, WY; Tyan, YC; Wu, CF; Yang, MH, 2022)
"This study aimed to evaluate the effectiveness of metformin and pioglitazone in combination with vitamin E on sonography grade and liver enzymes level in patients with non-alcoholic fatty liver disease."	5.69	Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. ( Beheshtirouy, S; Gharekhani, A; Khoshbaten, M; Rezaee, H; Shayanrad, S, 2023)
"Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world."	5.62	Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is one of the primary causes of chronic liver disease and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia."	5.62	Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. ( Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W, 2021)
"Rats treated with metformin showed a significant improvement in the aforementioned parameters."	5.56	Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020)
"Twelve weeks of treatment with metformin resulted in a significant reduction in body weight and improved insulin sensitivity, but IHTG content and FA oxidation remained unchanged."	5.51	Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. ( Charlton, C; Cornfield, T; Green, CJ; Hazlehurst, JM; Hodson, L; Marjot, T; McCullagh, J; Moolla, A; Pinnick, KE; Tomlinson, JW; Walsby-Tickle, J; Westcott, F, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world."	5.51	Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. ( Aguilar-Medina, EM; Centurión, D; de Jesús Acosta-Cota, S; Montes-Avila, J; Osuna-Martínez, U; Plazas-Guerrero, CG; Ramos-Payán, R; Rendón Maldonado, JG; Romero-Quintana, JG; Sánchez-López, A; Sarmiento-Sánchez, JI; Vergara-Jiménez, MJ, 2019)
"This pilot study suggests that the serum inflammatory markers at the average normal values point to the sufficiency of metformin-single therapy in inflammation control in non-obese T2DM patients with NAFLD."	5.51	Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD. ( Gluvic, Z; Isenovic, ER; Macut, D; Mitrovic, B; Obradovic, M; Soskic, S; Stajic, D; Sudar-Milovanovic, E, 2022)
"Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae."	5.51	Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. ( de Oliveira, S; Golenberg, N; Graves, AL; Houseright, RA; Huttenlocher, A; Korte, BG; Miskolci, V, 2019)
"Nonalcoholic fatty liver disease (NAFLD) is now a leading cause of chronic liver disease, and there is currently no available treatment strategy."	5.51	Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease. ( Chen, W; Fan, J; Hao, Q; Jin, X; Ju, D; Liu, H; Luan, J; Mei, X; Tang, S; Wu, Z; Zai, W; Zhang, X, 2019)
"Overall, MET reduced liver NAFLD but promoted hepatocyte increase in pro-inflammatory cytokines, thus, leading to liver inflammation."	5.48	Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. ( Alves, MJ; Araujo, AP; Batatinha, HA; Biondo, LA; Curi, R; de Souza Teixeira, AA; Hirabara, SM; Lima, EA; Neto, JCR; Sanches Silveira, L; Souza, CO, 2018)
"The metformin treatment largely reversed the correlations with diabetes-related pathways."	5.48	Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice. ( Cheng, Y; Cui, Q; Fang, W; Guo, J; Guo, L; Hu, G; Li, J; Lin, Y; Man, Y; Sun, M; Wei, J; Zhou, Y, 2018)
"Metformin treatment can improve NAFLD and decrease the level of chemerin."	5.42	Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). ( Jiang, D; Li, L; Li, X; Lou, F; Lou, N; Pan, Z; Sun, A; Sun, F; Zhang, L; Zhuang, X, 2015)
"To undertake a network meta-analysis to compare the relative efficacy of a dual peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonist, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin in patients with non-alcoholic fatty liver disease (NAFLD)."	5.41	PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis. ( Li, J; Wu, WH; Yan, Q; Zhang, H; Zhang, ZY; Zhao, Y, 2023)
"This is the first meta-analysis of the available literature about the efficacy of metformin exclusively in pediatric patients with non-alcoholic fatty liver disease (NAFLD)."	5.41	The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. ( Cheirakis, K; Christakopoulos, A; Fotoulaki, M; Gkiourtzis, N; Glava, A; Michou, P; Moutafi, M; Vouksinou, E, 2023)
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes."	5.38	Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012)
"To compare the effects of gliclazide, liraglutide and metformin on body composition in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease."	5.30	Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. ( Bi, Y; Feng, WH; Gao, CX; Gao, LJ; Li, P; Shen, SM; Yang, DH; Yin, TT; Zhu, DL, 2019)
"This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)."	5.27	Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018)
"The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)."	5.24	Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. ( Bi, Y; Chen, W; Feng, W; Gao, C; Li, P; Shen, S; Wu, M; Yin, T; Zhu, D, 2017)
"The Cochrane Library, PubMed, Scopus, and EMBASE database was systematically searched on 12 April 2022, using the keywords metformin; non-alcoholic fatty liver disease; and children to identify similar studies."	5.22	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. ( Chen, JA; Huang, JS; Huang, ZH; Lai, JM; Lin, MH; Peng, JY; Wu, QL; Xie, ZC; Yuan, Y; Zeng, SX; Zhu, Z, 2022)
"Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD."	5.17	Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. ( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013)
" Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial."	5.16	Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. ( Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R, 2012)
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3."	5.15	Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011)
"In our 6-month prospective study, both low-dose metformin and dietary treatment alone ameliorated liver steatosis and metabolic derangements in patients with NAFLD."	5.14	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. ( Abenavoli, L; Abenavoli, S; Belfiore, A; De Siena, M; Fruci, B; Garinis, GA; Greco, M; Gulletta, E; Mazza, A; Ventura, V, 2010)
" Metformin seems to be safe and presents evident positive effects on insulin sensitivity, but long-term and consistent data are still missing to establish its role in the pediatric population and the possible effectiveness of other emergent treatments such as glucagon-like peptide-1 analogues, dipeptidylpeptidase-4 inhibitors, dual inhibitors of SGLT1 and SGLT2 and weight loss drugs."	5.05	Metabolic syndrome in children. ( Chiarelli, F; Samvelyan, S; Tagi, VM, 2020)
"A MEDLINE, Pubmed and Cochrane Review database search using a combination of keywords, which included non-alcoholic fatty liver disease, non-alcoholic hepatic steatosis, NAFLD, NASH, treatment, therapeutics, vitamin E, orlistat and bariatric surgery."	4.90	Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. ( Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM, 2014)
"Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries."	4.88	Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012)
"Studies have confirmed that olanzapine, the mainstay treatment for schizophrenia, triggers metabolic diseases, including non-alcoholic fatty liver disease (NAFLD)."	4.12	Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway. ( Dai, W; Ding, C; Huang, P; Huang, X; Lian, P; Ran, J; Tang, Y; Zhu, W, 2022)
" Metformin serves as an AMPK activator and has been shown to have lipids lowering effects in non-alcoholic fatty liver disease (NAFLD), but its role in ALD remains unclear."	4.12	Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathway. ( Lv, Y; So, KF; Wang, D; Xiao, J; Xie, F; Zhong, Y, 2022)
"5 % cholic acid and 60 % cocoa butter for 6 weeks causing a number of metabolic and hepatic alterations including insulin resistance, dyslipidemia, systemic inflammation, increased hepatic oxidative stress and lipid peroxidation, hepatic steatosis, lobular inflammation, as well as increased markers of liver inflammation and hepatocyte apoptosis."	4.12	Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. ( Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A, 2022)
"We compared the efficacy of n3-polyunsaturated fatty acids (n3-PUFAs) and metformin in halting the progression of non-alcoholic fatty liver disease (NAFLD) developed in the milieu of insulin deficiency."	4.12	The hepatoprotective effects of n3-polyunsaturated fatty acids against non-alcoholic fatty liver disease in diabetic rats through the FOXO1/PPARα/GABARAPL1 signalling pathway. ( El-Mesery, A; Elmasry, K; Elsayed, HRH; Eraky, SM; Ramadan, NM, 2022)
" The effect of HFD on maternal rats was alleviated by prenatal metformin, which also ameliorated inflammation and apoptosis in the fetal liver and intestines."	4.02	Metformin ameliorates maternal high-fat diet-induced maternal dysbiosis and fetal liver apoptosis. ( Hou, CY; Huang, LT; Huang, SW; Lin, IC; Ou, YC; Sheen, JM; Tain, YL; Tang, KS; Tiao, MM; Tsai, CC; Yu, HR, 2021)
"Metformin (MET) and genistein (GEN) have a beneficial role in alleviating non-alcoholic fatty liver disease (NAFLD), but their combined effect on this disease has not yet been studied."	4.02	Combination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice. ( Bagherieh, M; Emamgholipour, S; Hashemnia, SMR; Meshkani, R; Shabani, M; Zamani-Garmsiri, F, 2021)
"Sixty-two obese patients in treatment with metformin-with prediabetes (n = 41) or newly diagnosed T2DM (n = 21), were studied."	4.02	Insulin resistance and NAFLD may influence memory performance in obese patients with prediabetes or newly-diagnosed type 2 diabetes. ( Ciotti, S; Cipollone, F; Consoli, A; Desideri, G; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tartaro, A; Tripaldi, R; Vadini, F, 2021)
"While the impact of metformin in hepatocytes leads to fatty acid (FA) oxidation and decreased lipogenesis, hepatic microRNAs (miRNAs) have been associated with fat overload and impaired metabolism, contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)."	3.96	Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes. ( Comas, F; Fernández-Real, JM; Höring, M; Latorre, J; Liebisch, G; Liñares-Pose, L; Lluch, A; López, M; Moreno-Navarrete, JM; Nidhina Haridas, PA; Oliveras-Cañellas, N; Olkkonen, VM; Ortega, FJ; Ricart, W; Zhou, Y, 2020)
"The current results suggest that exenatide is equivalent to metformin in controlling insulin resistance, body weight gain, improving liver function, suppressing inflammation, and attenuating NAFLD progression in male rats."	3.96	Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin. ( Ahmed, AAM; Khodeer, DM; Moustafa, YM; Saad, ZA; Zaitone, SA, 2020)
"The antidiabetic drug metformin has been proposed to affect non-alcoholic fatty liver disease (NAFLD) through its effects on intestinal microbiota and barrier function."	3.91	Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. ( Baumann, A; Bergheim, I; Brandt, A; Camarinha-Silva, A; Hernández-Arriaga, A; Jin, CJ; Kehm, R; Nier, A; Sánchez, V, 2019)
"Metformin may protect against hepatocellular carcinoma and mortality among patients with type 2 diabetes."	3.91	Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. ( Chalasani, N; Cummings, OW; Desai, AP; Gawrieh, S; Ghabril, M; Saxena, R; Vilar-Gomez, E; Vuppalanchi, R, 2019)
"To evaluate the impact of depression on NASH through the involvement of JNK1 and to assess the effect of sitagliptin and metformin on hepatic JNK1 expression in both NASH and NASH associated with depression."	3.85	Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. ( Abd-Elaziz, LF; Aboul-Fotouh, S; El-Kharashi, OA; Magdy, YM; Nabih, ES; Shaker, SM, 2017)
"To compare the effect of different hypoglycemic drugs on laboratory and ultrasonographic markers of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes not controlled on metformin alone."	3.83	Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. ( García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G, 2016)
"Metformin and phosphatidylcholine attenuated lipopolysaccharide induced toll-like receptor 4 overexpression and overproduction of pro-inflammatory cytokines; however, their efficacy depended on combined presence of non-alcoholic fatty liver disease, metabolic syndrome and obesity."	3.81	Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate. ( Daniluk, J; Kandefer-Szerszeń, M; Szuster-Ciesielska, A; Słabczyńska, O; Zwolak, A, 2015)
"Here, we sought to compare the efficacy of combining exercise and metformin for the treatment of type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) in hyperphagic, obese, type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats."	3.80	Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. ( Booth, FW; Crissey, JM; Fletcher, JA; Ibdah, JA; Kearney, ML; Laughlin, MH; Linden, MA; Meers, GM; Morris, EM; Rector, RS; Sowers, JR; Thyfault, JP, 2014)
"The administration of a HFD induces insulin resistance in the liver sinusoidal endothelium, which is mediated, at least in part, through iNOS upregulation and can be prevented by the administration of metformin."	3.77	Insulin resistance and liver microcirculation in a rat model of early NAFLD. ( Abraldes, JG; Bosch, J; García-Pagán, JC; La Mura, V; Pasarín, M; Rodríguez-Vilarrupla, A, 2011)
"To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet."	3.77	[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011)
" Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study."	3.77	Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011)
" Treatment-emergent adverse event incidence was similar across groups (40."	3.30	A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. ( Esler, WP; Khavandi, K; Kim, AM; Lyle, SA; Qiu, R; Saxena, AR; Whitlock, M, 2023)
"Combined treatment with pioglitazone-metformin can effectively reduce liver fat content and gamma-GT level in newly diagnosed diabetic patients with nonalcoholic fatty liver disease, and adverse events do not increase compared with the control group, showing good safety and tolerance."	3.30	Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study. ( Jianfang, F; Jianrong, L; Jie, M; Jing, X; Jingxuan, L; Kaiyan, M; Mengying, L; Qian, X; Qingzhen, H; Qiuhe, J; Taixiong, C; Wanxia, X; Wenjuan, Y; Xiling, G, 2023)
"A total of 50 patients with NAFLD and T2DM treated with metformin were randomized (1:1) to metformin plus add-on linagliptin (linagliptin group) or to an increased dose of metformin (metformin group) for 52 weeks."	3.01	Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. ( Hashiguchi, Y; Hosoyamada, K; Imamura, N; Kajiya, S; Kamada, T; Komorizono, Y; Koriyama, N; Shinmaki, H; Tsukasa, M; Ueyama, N, 2021)
"Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)."	2.94	Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. ( Guo, W; Lin, L; Tian, W; Xu, X, 2020)
"Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of liver disease worldwide."	2.90	Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. ( Duława, J; Handzlik, G; Holecki, M; Kędzierski, L; Kozaczka, J; Kukla, M; Pawlicki, K; Wyskida, K, 2019)
"Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and is becoming the most frequent indication of liver transplantation."	2.90	Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. ( Anushiravani, A; Haddadi, N; Mohammadkarimi, V; Pourfarmanbar, M, 2019)
"Metformin is first-line treatment of type 2 diabetes mellitus and reduces cardiovascular events in patients with insulin resistance and type 2 diabetes."	2.90	Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. ( Brøsen, K; Feddersen, S; Gormsen, LC; Grønbaek, H; Hamilton-Dutoit, SJ; Heebøll, S; Jakobsen, S; Jessen, N; Munk, OL; Pedersen, SB; Sundelin, EIO; Vendelbo, MH, 2019)
"Lobeglitazone-treated patients showed significantly decreased CAP values (313."	2.84	Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. ( Cho, YM; Jin, HY; Kim, JH; Kim, SR; Lee, BW; Lee, YH; Rhee, EJ, 2017)
"Whether metformin is related to nonalcoholic fatty liver disease (NAFLD) is controversial."	2.82	Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. ( Huang, Y; Li, C; Liang, E; Liu, T; Mao, J; Wang, X; Yan, C; Zhang, L, 2022)
"Metformin treatment was associated with a significant decrease in OPG levels in patients with NAFLD."	2.82	Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. ( Shargorodsky, M; Sofer, E, 2016)
"Bicyclol is a synthetic compound known to protect the liver against oxidation and lipid injuries."	2.79	Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. ( Ding, XD; Fan, JG; Han, Y; Ma, AL; Shi, JP; Xu, Y, 2014)
"Fetuin A levels were elevated in NAFLD."	2.77	Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. ( Aasheim, ET; Aukrust, P; Birkeland, KI; Dahl, TB; Gladhaug, IP; Haaland, T; Halvorsen, B; Haukeland, JW; Johansen, OE; Konopski, Z; Løberg, EM; Wium, C; Yndestad, A, 2012)
"Metformin treatment was associated with significant decrease in AI during one year treatment in NAFLD patients."	2.77	Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? ( Boaz, M; Gavish, D; Matas, Z; Omelchenko, E; Shargorodsky, M, 2012)
"Metformin treatment was associated with significant decrease in PWV and AI in NAFLD patients."	2.76	Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011)
" Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks."	2.76	Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011)
"However, most patients with NAFLD/NASH will die from a vascular cause."	2.72	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021)
"Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons for the increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels."	2.72	The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. ( Hu, H; Li, X; Meng, J; Shen, L; Shi, D; Wang, J, 2021)
"Metformin treatment has been shown to be effective at alleviating hepatic lipogenesis in animal models of NAFLD, with a variety of mechanisms being deemed responsible."	2.72	Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. ( Chattipakorn, N; Leerapun, A; Pinyopornpanish, K, 2021)
"Nonalcoholic fatty liver disease (NAFLD) is strongly linked to the global epidemic of obesity and type 2 diabetes mellitus (T2DM)."	2.72	Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. ( Wang, H; Xiao, H; Zhang, Y, 2021)
"Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease in both adults and children."	2.66	Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. ( Kohli, R; Lin, CH, 2020)
"Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases, of which the first stage is steatosis."	2.61	Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? ( Green, CJ; Hodson, L; Marjot, T; Tomlinson, JW, 2019)
"The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased substantially in the past two decades and NAFLD has now become the most common cause of chronic liver disease in children and adolescents."	2.58	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. ( Alkhouri, N; Conjeevaram Selvakumar, PK; Kabbany, MN, 2018)
"Metformin has been largely studied in the past years without convincing evidence of improving NAFLD."	2.58	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). ( Iogna Prat, L; Tsochatzis, EA, 2018)
"Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years."	2.58	Metformin: An Old Drug with New Applications. ( Li, L; Massey, S; Story, D; Zhou, J, 2018)
"Recently, fatty liver index and NAFLD fatty liver score analyzed in large cohorts of PCOS women have been shown as accurate markers of liver damage in this metabolically vulnerable population."	2.55	MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. ( Bjekić-Macut, J; Božić-Antić, I; Macut, D; Tziomalos, K, 2017)
"Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in the developed world (15% to 40% of the adult population)."	2.55	[Non-alcoholic liver disease - diagnosis and treatment]. ( Boniecka, I; Czerwonogrodzka-Senczyna, A; Ostrowska, J; Sarosiekjeznach-Steinhagen, A, 2017)
"Type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD) are highly prevalent in the community, and share common pathogenic mechanisms."	2.55	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? ( Caletti, MT; Forlani, G; Marchesini, G; Marchignoli, F; Mazzotti, A, 2017)
"The link between NAFLD/NASH and PCOS is not just a coincidence."	2.53	Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016)
"Diabetes and obesity are associated with nonalcoholic fatty liver disease (NAFLD) and an increased incidence of hepatocellular carcinoma (HCC)."	2.52	Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. ( Noureddin, M; Rinella, ME, 2015)
"Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and comprises a liver disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) with risk of progression to liver cirrhosis and hepatocellular carcinoma (HCC)."	2.52	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. ( Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Munda, P; Rechling, C; Trauner, M; Traussnigg, S, 2015)
"The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB)."	2.50	Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). ( Doycheva, I; Loomba, R, 2014)
"Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology."	2.50	Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. ( Abenavoli, L; Milic, N; Rouabhia, S, 2014)
"Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption."	2.50	Nonalcoholic fatty liver disease and polycystic ovary syndrome. ( Vassilatou, E, 2014)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."	2.50	Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide."	2.49	Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013)
"Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in hepatocytes in the absence of excessive alcohol intake, ranging in severity from simple steatosis to nonalcoholic steatohepatitis (NASH)."	2.49	Pharmacologic therapy for nonalcoholic fatty liver disease in adults. ( Bell, AM; Byrd, JS; Malinowski, SS; Riche, DM; Wofford, MR, 2013)
"Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis."	2.49	Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. ( Baldelli, E; Carulli, L; George, J; Hebbard, L; Loria, P; Maurantonio, M, 2013)
"Metformin is an antidiabetic drug used widely in clinical practice."	2.48	Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012)
"Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk."	2.47	[Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011)
"Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease worldwide."	2.47	Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. ( Ismail, MH, 2011)
"Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world."	2.47	Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011)
"Type 2 diabetes is a major health burden to the society."	1.91	Effects of metformin and simvastatin treatment on ultrastructural features of liver macrophages in HFD mice. ( Bumbasirevic, V; Ciric, D; Jovanovic, S; Kravic-Stevovic, T; Martinovic, T; Petricevic, S; Trajkovic, V, 2023)
"Consistently, TTP-deficient NAFLD mice failed to respond to metformin with respect to alleviation of hepatic steatosis, protection of hepatocyte necroptosis, or induction of lipophagy."	1.91	Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis. ( An, HS; Chung, HT; Joe, Y; Kim, UH; Lee, JY; Park, J; Park, JW; Rah, SY; Roh, GS; Ryter, SW; Surh, YJ; Yang, CH, 2023)
"Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world."	1.91	Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome. ( Augusto, CT; de la Paz Scribano Parada, M; Del Carmen Baez, M; Fonseca, I; Rossi, MM; Signorini, F, 2023)
"Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide."	1.91	Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS ( Andia, ME; Arrese, M; Aspichueta, P; Botnar, RM; Buqué, X; Eykyn, TR; Kumar, S; Lavin, B; Phinikaridou, A; Sing-Long, C; Xavier, A, 2023)
"Metformin (MET) has been demonstrated to have favorable impact on nonalcoholic fatty liver disease (NAFLD); however, the combined effect of this drug with p-coumaric acid (PCA) on liver steatosis is unclear."	1.91	Combination therapy of metformin and p-coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high-fat diet obese C57BL/6 mice. ( Bahramzadeh, A; Goodarzi, G; Meshkani, R; Panahi, G; Tehrani, SS, 2023)
"Common comorbidities were type 2 diabetes (56%), hyperlipidemia (44%), hypertension (46%), and obesity (42%)."	1.91	Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. ( Articolo, A; Charlton, M; Luthra, R; Shelley, K, 2023)
"In patients with NAFLD, those with type 2 diabetes mellitus (DM) have a high risk of progression to HCC."	1.72	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. ( Dai, J; El-Serag, HB; Kanwal, F; Kramer, JR; Li, L; Natarajan, Y; Yu, X, 2022)
"At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy."	1.72	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). ( Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is a common cause of clinical liver dysfunction and an important prepathological change of liver cirrhosis."	1.72	Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. ( Cui, W; Kong, L; Yang, X; Zhou, ST, 2022)
"Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidities and mortality, and no effective drug treatment currently exists."	1.72	Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase. ( Chen, AY; Chen, YA; Lee, YC; Li, WY; Tyan, YC; Wu, CF; Yang, MH, 2022)
"Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are serious health concerns for which lifestyle interventions are the only effective first-line treatment."	1.72	Combining Dietary Intervention with Metformin Treatment Enhances Non-Alcoholic Steatohepatitis Remission in Mice Fed a High-Fat High-Sucrose Diet. ( Amigó, N; Baiges-Gaya, G; Camps, J; Castañé, H; Jiménez-Franco, A; Joven, J; Rodríguez-Tomàs, E, 2022)
"Non-alcoholic fatty liver disease (NAFLD) was evaluated by abdominal ultrasound, and fibrosis stages were evaluated at baseline and 8 months."	1.72	The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. ( Fu, BY; Wang, XJ, 2022)
"Metformin use over time was associated with a significant reduction in risk of death or liver transplantation (aHR, 0."	1.62	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. ( Adams, LA; Aller-de la Fuente, R; Calzadilla-Bertot, L; Castellanos, M; Eslam, M; George, J; Romero-Gomez, M; Vilar-Gomez, E; Wong, GL; Wong, VW, 2021)
"Nonalcoholic fatty liver disease (NAFLD) has emerged as the leading liver disease globally."	1.62	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. ( Gawrieh, S; Khneizer, G; Rizvi, S, 2021)
"Non-alcoholic fatty liver disease (NAFLD) has become an important health problem in the world."	1.62	Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. ( Aliabadi, M; Emamgholipour, S; Ghasempour, G; Hashemnia, SMR; Meshkani, R; Zamani-Garmsiri, F, 2021)
"Metformin is a widely used first-line anti-diabetic drug."	1.62	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. ( Ahn, SH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Lee, JS; Park, JY, 2021)
" This model provides a simple but unique platform to evaluate aspects of an individual factor's contribution to NAFLD development and mechanisms as well as evaluate preclinical drug efficacy and reassess human dosing regimens."	1.62	Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation. ( Boone, R; Cai, Y; Hickman, JJ; Lambert, S; Long, CJ; Malik, D; McAleer, CW; Rumsey, JW; Shuler, ML; Slaughter, VL; Sriram, NN, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is one of the primary causes of chronic liver disease and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia."	1.62	Metformin in Combination with Malvidin Prevents Progression of Non-Alcoholic Fatty Liver Disease via Improving Lipid and Glucose Metabolisms, and Inhibiting Inflammation in Type 2 Diabetes Rats. ( Gu, X; Li, X; Zhang, C; Zhu, H; Zou, W, 2021)
"Rats treated with metformin showed a significant improvement in the aforementioned parameters."	1.56	Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. ( Abdel-Latif, RG; El-Deen, RM; Heeba, GH; Khalifa, MMA, 2020)
"The prevalence of nonalcoholic fatty liver disease (NAFLD) is significantly rising worldwide."	1.56	Medications in type-2 diabetics and their association with liver fibrosis. ( Al-Yaman, W; Amin, H; Chadalavada, P; Garg, R; Lopez, R; Siddiqui, MT; Singh, A, 2020)
"She had been suffering from type 2 diabetes mellitus since the age of 50 years."	1.56	Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. ( Fujimori, N; Horiuchi, A; Joshita, S; Kato, N; Kimura, T; Kuribayashi, N; Matsumoto, A; Sano, K; Sugiura, A; Takahashi, Y; Tanaka, E; Tanaka, N; Umemura, T; Yamazaki, T, 2020)
"Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world."	1.51	Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. ( Aguilar-Medina, EM; Centurión, D; de Jesús Acosta-Cota, S; Montes-Avila, J; Osuna-Martínez, U; Plazas-Guerrero, CG; Ramos-Payán, R; Rendón Maldonado, JG; Romero-Quintana, JG; Sánchez-López, A; Sarmiento-Sánchez, JI; Vergara-Jiménez, MJ, 2019)
"Treatment with metformin altered macrophage polarization, reduced liver size and reduced micronuclei formation in NAFLD/NASH-associated HCC larvae."	1.51	Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. ( de Oliveira, S; Golenberg, N; Graves, AL; Houseright, RA; Huttenlocher, A; Korte, BG; Miskolci, V, 2019)
"Nonalcoholic fatty liver disease (NAFLD) is now a leading cause of chronic liver disease, and there is currently no available treatment strategy."	1.51	Targeted Interleukin-22 Gene Delivery in the Liver by Polymetformin and Penetratin-Based Hybrid Nanoparticles to Treat Nonalcoholic Fatty Liver Disease. ( Chen, W; Fan, J; Hao, Q; Jin, X; Ju, D; Liu, H; Luan, J; Mei, X; Tang, S; Wu, Z; Zai, W; Zhang, X, 2019)
"Metformin use was an important factor in a subgroup, lowering FGF19, and resulting in bile acid diarrhea."	1.51	Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( Appleby, RN; Khan, S; Manousou, P; Moghul, I; Neal, TD; Walters, JRF; Yee, M, 2019)
"NAFLD is prevalent in patients with type 2 diabetes mellitus (T2DM), yet only preliminary evidence are available on the effect of anti-diabetic agents to NAFLD in T2DM patients."	1.51	Reply. ( Weng, J, 2019)
"The hepatoprotective effect of Cs on NAFLD may possibly be due to its antioxidant effect."	1.51	Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat. ( Fang, N; Guo, Y; Liu, Y; Meng, Y, 2019)
" The easy and convenient oncedaily dosing should be customized according to patient needs and glycaemic profiles."	1.51	Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. ( Aamir, AH; Ahmad, I; Ishtiaq, O; Islam, N; Jawa, A; Khan, K; Khan, KM; Mahar, SA; Naseer, N; Qureshi, FM; Raza, SA, 2019)
"Overall, MET reduced liver NAFLD but promoted hepatocyte increase in pro-inflammatory cytokines, thus, leading to liver inflammation."	1.48	Short-term treatment with metformin reduces hepatic lipid accumulation but induces liver inflammation in obese mice. ( Alves, MJ; Araujo, AP; Batatinha, HA; Biondo, LA; Curi, R; de Souza Teixeira, AA; Hirabara, SM; Lima, EA; Neto, JCR; Sanches Silveira, L; Souza, CO, 2018)
"The metformin treatment largely reversed the correlations with diabetes-related pathways."	1.48	Metformin-Induced Changes of the Coding Transcriptome and Non-Coding RNAs in the Livers of Non-Alcoholic Fatty Liver Disease Mice. ( Cheng, Y; Cui, Q; Fang, W; Guo, J; Guo, L; Hu, G; Li, J; Lin, Y; Man, Y; Sun, M; Wei, J; Zhou, Y, 2018)
"Non‑alcoholic fatty liver disease (NAFLD), which affects approximately one‑third of the general population, has become a global health problem."	1.48	Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. ( Gao, S; Huang, D; Huang, J; Tong, P; Wang, Y; Wu, X; Yue, Y; Zhao, J, 2018)
"Metformin treatment remarkably improved liver function, alleviated lipid peroxidation and histological damages of the liver, and ameliorated glucose intolerance and insulin resistance."	1.43	Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. ( Chen, F; Liu, Y; Ping, J; Ruo, R; Shou, Q; Xu, H; Zhou, Y, 2016)
"Patients with nonalcoholic steatohepatitis (NASH) had similar demographic and anthropometric features, but a higher prevalence of type 2 diabetes (T2D; p = 0."	1.43	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. ( Borroni, V; Bugianesi, E; Craxi, A; Dongiovanni, P; Fargion, S; Fracanzani, AL; Pelusi, S; Petta, S; Rosso, C; Valenti, L, 2016)
"Metformin is an antihyperglycemic drug that is widely prescribed for type 2 diabetes mellitus and is currently being investigated for the treatment of nonalcoholic steatohepatitis (NASH)."	1.42	Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. ( Cherrington, NJ; Clarke, JD; Dzierlenga, AL; Goedken, MJ; Li, H; Nelson, NR; Werts, S, 2015)
"Metformin treatment prevented acute stress-induced necroinflammatory reaction, reduced alanine aminotransferase and aspartate aminotransferase serum activity, and diminished lipoperoxidation."	1.42	Metformin prevents ischemia reperfusion-induced oxidative stress in the fatty liver by attenuation of reactive oxygen species formation. ( Burian, M; Cahova, M; Cervinkova, Z; Dankova, H; Drahota, Z; Gladkova, C; Kazdova, L; Krizova, J; Kucera, O; Oliyarnyk, O; Palenickova, E; Papackova, Z; Sticova, E; Stopka, P, 2015)
"Metformin treatment led to a comparable reduction in plasma insulin levels in both C57BL/6 and apoa1(-/-) mice following intraperitoneal glucose tolerance test."	1.42	Deficiency in apolipoprotein A-I ablates the pharmacological effects of metformin on plasma glucose homeostasis and hepatic lipid deposition. ( Constantinou, C; Hatziri, A; Kalogeropoulou, C; Karavia, EA; Kypreos, KE; Natsos, A; Papachristou, DJ; Papachristou, NI; Petropoulou, PI; Sasson, S; Xepapadaki, E, 2015)
"Metformin treatment can improve NAFLD and decrease the level of chemerin."	1.42	Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). ( Jiang, D; Li, L; Li, X; Lou, F; Lou, N; Pan, Z; Sun, A; Sun, F; Zhang, L; Zhuang, X, 2015)
"From the 479 patients with NAFLD assessed, 302 patients (63%) greater than 18 years old were included."	1.39	NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. ( Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S, 2013)
"Metformin has recently drawn attention because of its potential antitumor effect."	1.39	Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. ( Aoki, K; Atsumi, T; Inoue, H; Ito, Y; Kaji, M; Nagashima, Y; Nakamura, A; Orime, K; Sakamoto, E; Sato, K; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y, 2013)
"Metformin can increase the expression of SIRT1 and reduce the expression of UCP2, with negative correlation between the expression of SIRT1 and UCP2."	1.39	[Effect of metformin on the expression of SIRT1 and UCP2 in rat liver of type 2 diabetes mellitus and nonalcoholic fatty liver]. ( Ding, S; Jiao, Y; Li, N; Wang, J; Xu, J; Zhang, C; Zhang, J, 2013)
"Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues."	1.38	Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease. ( Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C, 2012)
"Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance."	1.38	Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin. ( Korbut, R; Madej, J; Okoń, K; Olszanecki, R; Stachowicz, A; Suski, M, 2012)
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes."	1.38	Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012)
"non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress."	1.37	Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. ( Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R, 2011)

Research

Studies (191)

Authors

Clinical Trials (21)

Trial Overview

Trial Outcomes

Change in Body Mass Index

Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	115 (60.21)	24.3611
2020's	76 (39.79)	2.80

Authors	Studies
Ma, L	1
Xie, C	1
Ran, Y	1
Liang, X	1
Huang, L	1
Pei, H	1
Chen, J	2
Liu, J	1
Sang, Y	1
Lai, H	1
Peng, A	1
Xiang, M	1
Wei, Y	3
Chen, L	4
Huang, SW	1
Ou, YC	1
Tang, KS	1
Yu, HR	4
Huang, LT	4
Tain, YL	4
Lin, IC	4
Sheen, JM	4
Hou, CY	1
Tsai, CC	4
Tiao, MM	4
Majnooni, MB	1
Ataee, M	1
Bahrami, G	1
Heydarpour, F	1
Aneva, IY	1
Farzaei, MH	1
Ahmadi-Juoibari, T	1
Kramer, JR	1
Natarajan, Y	1
Dai, J	1
Yu, X	1
Li, L	3
El-Serag, HB	1
Kanwal, F	1
Lavynenko, O	1
Abdul-Ghani, M	1
Alatrach, M	1
Puckett, C	1
Adams, J	1
Abdelgani, S	1
Alkhouri, N	2
Triplitt, C	1
Clarke, GD	1
Vasquez, JA	1
Li, J	10
Cersosimo, E	1
Gastaldelli, A	1
DeFronzo, RA	1
Green, CJ	2
Marjot, T	2
Walsby-Tickle, J	1
Charlton, C	1
Cornfield, T	1
Westcott, F	1
Pinnick, KE	1
Moolla, A	1
Hazlehurst, JM	1
McCullagh, J	1
Tomlinson, JW	2
Hodson, L	2
Lule, KO	1
Akarsu, E	1
Sayiner, ZA	1
Lule, NO	1
Balci, SO	1
Demirel, C	1
Bozdag, Z	1
Korkmaz, M	1
Yilmaz, I	1
Su, Y	1
Lu, S	1
Hou, C	1
Ren, K	1
Wang, M	1
Liu, X	3
Zhao, S	2
Wabitsch, S	1
McCallen, JD	1
Kamenyeva, O	1
Ruf, B	1
McVey, JC	1
Kabat, J	1
Walz, JS	1
Rotman, Y	1
Bauer, KC	1
Craig, AJ	1
Pouzolles, M	1
Phadke, I	1
Catania, V	1
Green, BL	1
Fu, C	1
Diggs, LP	1
Heinrich, B	1
Wang, XW	2
Ma, C	1
Greten, TF	1
Zhu, W	1
Ding, C	1
Huang, P	1
Ran, J	1
Lian, P	1
Tang, Y	1
Dai, W	1
Huang, X	1
Wu, G	2
Dai, Y	1
Yan, Y	1
Zheng, X	1
Zhang, H	3
Li, H	6
Chen, W	5
Zhou, ST	1
Cui, W	1
Kong, L	1
Yang, X	5
Lujambio, A	1
Sarobe, P	1
Xie, F	1
Zhong, Y	1
Wang, D	2
So, KF	1
Xiao, J	1
Lv, Y	1
Wu, QL	1
Zeng, SX	1
Peng, JY	1
Yuan, Y	1
Zhu, Z	1
Xie, ZC	1
Huang, ZH	1
Huang, JS	1
Lai, JM	1
Chen, JA	1
Lin, MH	1
Wang, X	7
Zhao, B	1
Sun, H	2
You, H	1
Qu, S	1
Yang, MH	1
Li, WY	1
Wu, CF	1
Lee, YC	1
Chen, AY	1
Tyan, YC	1
Chen, YA	1
Shaaban, HH	1
Alzaim, I	1
El-Mallah, A	1
Aly, RG	1
El-Yazbi, AF	1
Wahid, A	1
Li, M	2
Liu, L	3
Kang, Y	1
Huang, S	1
Xiao, Y	1
Huang, Y	3
Yan, C	1
Li, C	2
Zhang, L	5
Liang, E	1
Liu, T	1
Mao, J	1
Ramadan, NM	1
Elmasry, K	1
Elsayed, HRH	1
El-Mesery, A	1
Eraky, SM	1
Azit, NA	3
Sahran, S	3
Meng, LV	3
Subramaniam, MK	3
Mokhtar, S	3
Nawi, AM	3
Huang, CF	3
Hsu, CN	3
Lin, YJ	3
Saxena, AR	2
Lyle, SA	2
Khavandi, K	2
Qiu, R	2
Whitlock, M	2
Esler, WP	2
Kim, AM	2
Ciric, D	2
Kravic-Stevovic, T	2
Bumbasirevic, V	2
Petricevic, S	2
Jovanovic, S	2
Trajkovic, V	2
Martinovic, T	2
Huang, KH	1
Lee, CH	1
Cheng, YD	1
Gau, SY	1
Tsai, TH	1
Chung, NJ	1
Lee, CY	1
Baiges-Gaya, G	1
Rodríguez-Tomàs, E	1
Castañé, H	1
Jiménez-Franco, A	1
Amigó, N	1
Camps, J	1
Joven, J	1
Liu, B	1
Xu, J	2
Lu, L	1
Gao, L	1
Zhu, S	1
Sui, Y	1
Cao, T	2
Yang, T	3
Park, J	1
Rah, SY	1
An, HS	1
Lee, JY	1
Roh, GS	1
Ryter, SW	1
Park, JW	1
Yang, CH	1
Surh, YJ	1
Kim, UH	1
Chung, HT	1
Joe, Y	1
Khoshbaten, M	1
Beheshtirouy, S	1
Shayanrad, S	1
Gharekhani, A	1
Rezaee, H	1
Augusto, CT	1
de la Paz Scribano Parada, M	1
Rossi, MM	1
Signorini, F	1
Fonseca, I	1
Del Carmen Baez, M	1
Lavin, B	1
Eykyn, TR	1
Phinikaridou, A	1
Xavier, A	1
Kumar, S	1
Buqué, X	1
Aspichueta, P	1
Sing-Long, C	1
Arrese, M	1
Botnar, RM	1
Andia, ME	1
Tehrani, SS	2
Goodarzi, G	2
Panahi, G	2
Zamani-Garmsiri, F	3
Meshkani, R	4
Bahramzadeh, A	1
Shelley, K	1
Articolo, A	1
Luthra, R	1
Charlton, M	2
Ma, YL	1
Ke, JF	1
Wang, JW	1
Wang, YJ	1
Xu, MR	1
Li, LX	1
Jianfang, F	1
Wanxia, X	1
Xiling, G	1
Jing, X	1
Wenjuan, Y	1
Jianrong, L	1
Qingzhen, H	1
Kaiyan, M	1
Jingxuan, L	1
Taixiong, C	1
Qian, X	1
Mengying, L	1
Jie, M	1
Qiuhe, J	1
Zhang, ZY	1
Yan, Q	1
Wu, WH	1
Zhao, Y	3
Sarkar, K	1
Bank, S	1
Chatterjee, A	1
Dutta, K	1
Das, A	1
Chakraborty, S	1
Paul, N	1
Sarkar, J	1
De, S	1
Ghosh, S	1
Acharyya, K	1
Chattopadhyay, D	1
Das, M	1
Melnyk, S	1
Hakkak, R	1
Gkiourtzis, N	1
Michou, P	1
Moutafi, M	1
Glava, A	1
Cheirakis, K	1
Christakopoulos, A	1
Vouksinou, E	1
Fotoulaki, M	1
Ratziu, V	1
Pais, R	1
Oliveira, CP	1
Cotrim, HP	1
Stefano, JT	1
Siqueira, ACG	1
Salgado, ALA	1
Parise, ER	1
Dogru, T	1
Kırık, A	1
Sonmez, A	1
Vilar-Gomez, E	3
Chalasani, N	7
de Jesús Acosta-Cota, S	1
Aguilar-Medina, EM	1
Ramos-Payán, R	1
Rendón Maldonado, JG	1
Romero-Quintana, JG	1
Montes-Avila, J	1
Sarmiento-Sánchez, JI	1
Plazas-Guerrero, CG	1
Vergara-Jiménez, MJ	1
Sánchez-López, A	1
Centurión, D	1
Osuna-Martínez, U	1
Taneja, V	1
Yang, D	2
Yan, J	2
Weng, J	3
Serfaty, L	1
Blazina, I	1
Selph, S	1
Geng, Y	1
Hernández Villanueva, A	1
Oun, A	1
Buist-Homan, M	1
Blokzijl, H	1
Faber, KN	1
Dolga, A	1
Moshage, H	1
Horn, P	1
Newsome, PN	1
Mantovani, A	1
Byrne, CD	1
Scorletti, E	1
Mantzoros, CS	2
Targher, G	1
Heeba, GH	2
El-Deen, RM	1
Abdel-Latif, RG	1
Khalifa, MMA	1
Latorre, J	1
Ortega, FJ	1
Liñares-Pose, L	1
Moreno-Navarrete, JM	1
Lluch, A	1
Comas, F	1
Oliveras-Cañellas, N	1
Ricart, W	1
Höring, M	1
Zhou, Y	3
Liebisch, G	1
Nidhina Haridas, PA	1
Olkkonen, VM	1
López, M	1
Fernández-Real, JM	1
Tagi, VM	1
Samvelyan, S	1
Chiarelli, F	2
Saad, ZA	1
Khodeer, DM	1
Zaitone, SA	1
Ahmed, AAM	1
Moustafa, YM	1
Calzadilla-Bertot, L	1
Wong, VW	1
Castellanos, M	1
Aller-de la Fuente, R	1
Eslam, M	1
Wong, GL	1
George, J	2
Romero-Gomez, M	1
Adams, LA	1
Khneizer, G	1
Rizvi, S	1
Gawrieh, S	3
Mahjoubin-Tehran, M	1
De Vincentis, A	1
Mikhailidis, DP	1
Atkin, SL	2
Jamialahmadi, T	1
Sahebkar, A	3
Siddiqui, MT	1
Amin, H	1
Garg, R	1
Chadalavada, P	1
Al-Yaman, W	1
Lopez, R	1
Singh, A	2
Ahmed, LA	1
Salem, MB	1
Seif El-Din, SH	1
El-Lakkany, NM	1
Ahmed, HO	1
Nasr, SM	1
Hammam, OA	1
Botros, SS	1
Saleh, S	1
Lin, CH	1
Kohli, R	1
Nguépy Keubo, FR	1
Mboua, PC	1
Djifack Tadongfack, T	1
Fokouong Tchoffo, E	1
Tasson Tatang, C	1
Ide Zeuna, J	1
Noupoue, EM	1
Tsoplifack, CB	1
Folefack, GO	1
Kettani, M	1
Bandelier, P	1
Huo, J	1
Yu, D	1
Arulsamy, N	1
AlAbbad, S	1
Sardot, T	1
Lekashvili, O	1
Decato, D	1
Lelj, F	1
Alexander Ross, JB	1
Rosenberg, E	1
Nazir, H	1
Muthuswamy, N	1
Louis, C	1
Jose, S	1
Prakash, J	1
Buan, MEM	1
Flox, C	1
Chavan, S	1
Shi, X	1
Kauranen, P	1
Kallio, T	1
Maia, G	1
Tammeveski, K	1
Lymperopoulos, N	1
Carcadea, E	1
Veziroglu, E	1
Iranzo, A	1
M Kannan, A	1
Arunamata, A	1
Tacy, TA	1
Kache, S	1
Mainwaring, RD	1
Ma, M	1
Maeda, K	1
Punn, R	1
Noguchi, S	1
Hahn, S	3
Iwasa, Y	3
Ling, J	2
Voccio, JP	2
Kim, Y	3
Song, J	3
Bascuñán, J	2
Chu, Y	1
Tomita, M	1
Cazorla, M	1
Herrera, E	1
Palomeque, E	1
Saud, N	1
Hoplock, LB	1
Lobchuk, MM	1
Lemoine, J	1
Li, X	14
Henson, MA	1
Unsihuay, D	1
Qiu, J	1
Swaroop, S	1
Nagornov, KO	1
Kozhinov, AN	1
Tsybin, YO	1
Kuang, S	1
Laskin, J	1
Zin, NNINM	1
Mohamad, MN	1
Roslan, K	1
Abdul Wafi, S	1
Abdul Moin, NI	1
Alias, A	1
Zakaria, Y	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of DPP-4I and Related Treatment on Non-alcoholic Fatty Liver Disease[NCT05480007]		68 participants (Actual)	Interventional	2011-01-30	Completed
A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471]		45 participants (Anticipated)	Observational	2021-06-30	Not yet recruiting
Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy[NCT05301231]		450 participants (Anticipated)	Observational [Patient Registry]	2022-08-01	Not yet recruiting
Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2019-01-09	Completed
[NCT01084486]	Phase 1/Phase 2	0 participants	Interventional		Completed
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158]	Phase 3	56 participants (Anticipated)	Interventional	2022-11-30	Not yet recruiting
[NCT02285205]	Phase 4	38 participants (Actual)	Interventional	2014-11-30	Completed
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635]	Phase 3	173 participants (Actual)	Interventional	2005-09-30	Completed
Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405]	Phase 4	24 participants (Actual)	Interventional	2007-06-30	Completed
Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)[NCT00303537]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2004-11-30	Active, not recruiting
Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis[NCT02526732]		44 participants (Actual)	Interventional	2015-09-30	Completed
The Effects of Type of Exercise on Hepatic Fat Content and Metabolic Profiles in Non-alcoholic Fatty Liver Disease: A Randomized Trial[NCT02679417]		38 participants (Actual)	Interventional	2015-08-31	Completed
A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH[NCT02933554]		8 participants (Anticipated)	Interventional	2024-06-30	Not yet recruiting
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and Nonalcoholic Steatohepatitis in Biopsy-Proven NAFLD Patients[NCT03725631]		150 participants (Anticipated)	Interventional	2016-09-01	Recruiting
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-16	Recruiting
An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)[NCT02653300]	Phase 2	10 participants (Actual)	Interventional	2018-09-20	Completed
Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients[NCT04779905]		62 participants (Actual)	Observational	2021-02-28	Completed
Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)[NCT03375008]		47 participants (Actual)	Interventional	2016-09-08	Completed
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis[NCT03061721]	Phase 2	106 participants (Actual)	Interventional	2017-04-06	Completed
A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04618744]	Phase 2	33 participants (Actual)	Interventional	2020-11-24	Completed
Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806]	Phase 4	15 participants (Anticipated)	Interventional	2022-10-10	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	kg/m-squared (Mean)
Metformin	1.3
Vitamin E	2.1
Placebo	1.9

Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks

Change in QOL- Psychosocial Health

Intervention	units on a scale (Mean)
Metformin	-1.1
Vitamin E	-1.8
Placebo	-0.7

Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks

Change in Quality of Life (QOL) Scores- Physical Health

Intervention	units on a scale (Mean)
Metformin	4.0
Vitamin E	6.0
Placebo	5.6

Change in Serum Aspartate Aminotransferase (AST)

Change in Serum Vitamin E Levels

Number of Participants With Improvement in Ballooning Degradation Score

Intervention	units on a scale (Mean)
Metformin	5.4
Vitamin E	7.6
Placebo	5.4

Intervention	IU/L (Mean)
Metformin	-21.5
Vitamin E	-22.8
Placebo	-20.4

Intervention	mg/L (Mean)
Metformin	-0.5
Vitamin E	9.4
Placebo	-0.9

Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Liver Fibrosis Score

Intervention	participants (Number)
Metformin	22
Vitamin E	22
Placebo	10

Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Lobular Inflammation Score

Intervention	participants (Number)
Metformin	22
Vitamin E	18
Placebo	19

Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks

Number of Participants With Improvement in Steatosis Score

Intervention	participants (Number)
Metformin	23
Vitamin E	22
Placebo	20

Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks

Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L

Intervention	participants (Number)
Metformin	26
Vitamin E	27
Placebo	19

The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks

Hepatic Fat

Intervention	participants (Number)
Metformin	9
Vitamin E	15
Placebo	10

The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year

Plasma Adipocytokines

Intervention	percent of liver fat (Mean)
Pioglitazone and Exenatide	4.7
Pioglitazone	6.5

the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year

Change in MRI-Proton Density Fat Fraction (MRI-PDFF)

Intervention	microgram per ml (Mean)
Pioglitazone and Exenatide	23.2
Pioglitazone	15.8

Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12 (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12

Mean Fibrosis Score CAP™ (FibroMax)

Intervention	percentage fat in the liver (Mean)
	MRPDFF (%) at baseline	MR PDFF (%) at Week 12	Absolute Mean Change in MR PDFF (%) from Baseline
Oral Insulin	21.3	14.4	-6.9

Mean fibrosis score (severity scale of liver fibrosis) measured at baseline and week 12. Fibrosis Score CAP measures the amount of steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m with higher values indicating more fatty change (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12

Mean Transient Elastography Measurement (Fibroscan)

Intervention	dB/M (Mean)
	Mean Fibrosis Score at Baseline	Mean Fibrosis Score at week 12
Oral Insulin	338.5	315.5

Mean Transient elasticity, measured in kPA (kilo Pascal), (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12

Article	Year
Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. Expert review of gastroenterology & hepatology, 2022, Volume: 16, Issue:9 Topics: Anti-Inflammatory Agents; Child; Diabetes Mellitus, Type 2; Humans; Insulin; Metformin; Non-alcoholi	2022
Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine, 2022, Oct-28, Volume: 101, Issue:43 Topics: Class I Phosphatidylinositol 3-Kinases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Metfo	2022
PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis. The Journal of international medical research, 2023, Volume: 51, Issue:6 Topics: Glucagon-Like Peptide-1 Receptor; Humans; Metformin; Network Meta-Analysis; Non-alcoholic Fatty Live	2023
The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. European journal of pediatrics, 2023, Volume: 182, Issue:11 Topics: Alanine Transaminase; Child; Humans; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liv	2023
[Pharmacological treatment of NASH]. Presse medicale (Paris, France : 1983), 2019, Volume: 48, Issue:12 Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Cytoprotection; Glucagon-Like Peptide 1; Humans; Imi	2019
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Systematic reviews, 2019, 11-29, Volume: 8, Issue:1 Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide	2019
Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & metabolism, 2020, Volume: 46, Issue:6 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Hum	2020
Metabolic syndrome in children. Minerva pediatrica, 2020, Volume: 72, Issue:4 Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Cardiovascular Diseases; Child; Dipeptidyl-Pepti	2020
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular metabolism, 2021, Volume: 50 Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di	2021
Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease. Current gastroenterology reports, 2020, Aug-19, Volume: 22, Issue:10 Topics: Adolescent; Alanine Transaminase; Antioxidants; Bariatric Surgery; Child; Child, Preschool; Cysteami	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli	2021
The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. Current pharmaceutical design, 2021, Volume: 27, Issue:29 Topics: Alanine Transaminase; Body Mass Index; Humans; Insulin Resistance; Metformin; Non-alcoholic Fatty Li	2021
Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. Gut and liver, 2021, 11-15, Volume: 15, Issue:6 Topics: Adult; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Liver Neoplasms; Metf	2021
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. Frontiers in endocrinology, 2021, Volume: 12 Topics: Alanine Transaminase; Aspartate Aminotransferases; Bayes Theorem; Blood Glucose; Body Mass Index; Bo	2021
Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC. International journal of molecular sciences, 2021, May-09, Volume: 22, Issue:9 Topics: Animals; Carcinoma, Hepatocellular; Disease Progression; Disease Susceptibility; DNA Damage; Hepatoc	2021
Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. Inflammopharmacology, 2021, Volume: 29, Issue:4 Topics: Adiponectin; alpha-2-HS-Glycoprotein; Animals; Anti-Inflammatory Agents; Caloric Restriction; Humans	2021
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nature reviews. Endocrinology, 2021, Volume: 17, Issue:10 Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Growth Differentiation Factor 15; Human	2021
MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. European journal of endocrinology, 2017, Volume: 177, Issue:3 Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Liraglutide; Metformin; Non-alcoholic Fatty	2017
[Non-alcoholic liver disease - diagnosis and treatment]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2017, Nov-23, Volume: 43, Issue:257 Topics: Biopsy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Non-	2017
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, Volume: 272 Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Disea	2018
Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. Paediatric drugs, 2018, Volume: 20, Issue:4 Topics: Adolescent; Bariatric Surgery; Child; Diet Therapy; Humans; Metformin; Non-alcoholic Fatty Liver Dis	2018
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones (Athens, Greece), 2018, Volume: 17, Issue:2 Topics: Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone	2018
Metformin: An Old Drug with New Applications. International journal of molecular sciences, 2018, Sep-21, Volume: 19, Issue:10 Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metform	2018
Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4 Topics: Animals; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipo	2019
Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. BioMed research international, 2019, Volume: 2019 Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Glucose; Hepacivirus; Hepatitis B; Hepatitis	2019
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1 Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Me	2014
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. International journal of molecular sciences, 2013, Nov-20, Volume: 14, Issue:11 Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re	2013
The role of medications for the management of patients with NAFLD. Clinics in liver disease, 2014, Volume: 18, Issue:1 Topics: Antioxidants; Fatty Liver; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Me	2014
Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Advances in therapy, 2014, Volume: 31, Issue:1 Topics: Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Hepatocytes; Humans; Hypoglycemic Agents; Insu	2014
Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:4 Topics: Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Non-alcoholic Fatty	2014
Nonalcoholic fatty liver disease and polycystic ovary syndrome. World journal of gastroenterology, 2014, Jul-14, Volume: 20, Issue:26 Topics: Adiposity; Animals; Caloric Restriction; Comorbidity; Exercise; Female; Humans; Hypoglycemic Agents;	2014
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. Postgraduate medicine, 2014, Volume: 126, Issue:6 Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp	2014
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clinics in liver disease, 2015, Volume: 19, Issue:2 Topics: Carcinoma, Hepatocellular; Chemoprevention; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress;	2015
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4 Topics: Anticholesteremic Agents; Antioxidants; Bariatric Surgery; Carcinoma, Hepatocellular; Disease Progre	2015
Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver. Pharmacological reports : PR, 2015, Volume: 67, Issue:4 Topics: Animals; Drug Delivery Systems; Endothelial Cells; Hepatic Stellate Cells; Hepatocytes; Humans; Live	2015
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in liver disease, 2016, Volume: 20, Issue:2 Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anti	2016
Hepatic manifestations of women with polycystic ovary syndrome. Best practice & research. Clinical obstetrics & gynaecology, 2016, Volume: 37 Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo	2016
Gastrointestinal Conditions in the Obese Patient. Adolescent medicine: state of the art reviews, 2016,Spring, Volume: 27, Issue:1 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Constipation; Contraceptiv	2016
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:3 Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Non-al	2017
[Fatty liver and its clinical management in obese adolescents]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:1 Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros	2011
Use of metformin in pediatric age. Pediatric diabetes, 2011, Volume: 12, Issue:6 Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty	2011
Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. The American journal of the medical sciences, 2011, Volume: 341, Issue:6 Topics: Bariatric Surgery; Biopsy; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Fatty Liver; Hu	2011
Management of metabolic syndrome in children and adolescents. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2011, Volume: 21, Issue:6 Topics: Adolescent; Antioxidants; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Diabet	2011
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:38 Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents;	2011
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. Minerva endocrinologica, 2012, Volume: 37, Issue:1 Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones;	2012
Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. Current medicinal chemistry, 2012, Volume: 19, Issue:18 Topics: Animals; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Non-alcoholic Fatty Liver Disea	2012
Pharmacologic therapy for nonalcoholic fatty liver disease in adults. Pharmacotherapy, 2013, Volume: 33, Issue:2 Topics: Adult; Animals; Disease Progression; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi	2013
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. Current pharmaceutical design, 2013, Volume: 19, Issue:29 Topics: Carcinoma, Hepatocellular; Child; Fatty Liver; Humans; Hypoglycemic Agents; Liver Neoplasms; Metform	2013

Article	Year
The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial. Phytotherapy research : PTR, 2021, Volume: 35, Issue:11 Topics: Alanine Transaminase; Cynara scolymus; Dietary Supplements; Humans; Liver; Metformin; Non-alcoholic	2021
Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. European journal of endocrinology, 2022, Feb-07, Volume: 186, Issue:3 Topics: Adult; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents;	2022
Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease. Frontiers in endocrinology, 2022, Volume: 13 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; H	2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:4 Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Metformin; Non-a	2023
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:4 Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Metformin; Non-a	2023
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:4 Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Metformin; Non-a	2023
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:4 Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Metformin; Non-a	2023
Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial. Drug research, 2023, Volume: 73, Issue:4 Topics: Alanine Transaminase; Aspartate Aminotransferases; Humans; Hypoglycemic Agents; Metformin; Non-alcoh	2023
Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study. Journal of diabetes research, 2023, Volume: 2023 Topics: Diabetes Mellitus, Type 2; Humans; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Table	2023
N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. Arquivos de gastroenterologia, 2019, Aug-13, Volume: 56, Issue:2 Topics: Acetylcysteine; Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Male; Metformin;	2019
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli	2021
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes research and clinical practice, 2020, Volume: 170 Topics: Adult; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema	2020
Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-LINK study. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated H	2021
Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD. Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:1 Topics: Adult; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Human	2022
Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. The Journal of pediatrics, 2021, Volume: 239 Topics: Adolescent; Area Under Curve; Biopsy; Child; Double-Blind Method; Drug Therapy, Combination; Female;	2021
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. Journal of diabetes, 2017, Volume: 9, Issue:8 Topics: Adipose Tissue; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyc	2017
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:2 Topics: Adiposity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans	2018
Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:12 Topics: Adult; Alanine Transaminase; Cohort Studies; Double-Blind Method; Drug Combinations; Female; Humans;	2018
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. Journal of diabetes investigation, 2019, Volume: 10, Issue:2 Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Fem	2019
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:6 Topics: Adult; Aged; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dose-Response Relat	2019
Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacological reports : PR, 2019, Volume: 71, Issue:2 Topics: Adult; Blood Cell Count; Combined Modality Therapy; Elasticity Imaging Techniques; Female; Humans; H	2019
Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:5 Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucos	2019
Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. British journal of clinical pharmacology, 2019, Volume: 85, Issue:8 Topics: Adult; Aged; Biopsy; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Female; Gene Expression Profil	2019
Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clinical drug investigation, 2014, Volume: 34, Issue:1 Topics: Alanine Transaminase; Biphenyl Compounds; Drug Therapy, Combination; Female; Humans; Hypoglycemia; L	2014
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arquivos brasileiros de endocrinologia e metabologia, 2013, Volume: 57, Issue:9 Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Blood Glucose; Body Mass Index; Body Weight; C-React	2013
Does metformin treatment influence bone formation in patients with nonalcoholic fatty liver disease? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015, Volume: 47, Issue:8 Topics: Adult; Aged; Biomarkers; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Mi	2015
Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. Hepatology international, 2016, Volume: 10, Issue:1 Topics: Adult; Aged; Alkaline Phosphatase; Double-Blind Method; Down-Regulation; Female; Humans; Hypoglycemi	2016
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. Clinical endocrinology, 2016, Volume: 85, Issue:4 Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Huma	2016
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. Journal of Korean medical science, 2017, Volume: 32, Issue:1 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Elasticity Imag	2017
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. Journal of Korean medical science, 2017, Volume: 32, Issue:1 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Elasticity Imag	2017
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. Journal of Korean medical science, 2017, Volume: 32, Issue:1 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Elasticity Imag	2017
Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. Journal of Korean medical science, 2017, Volume: 32, Issue:1 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Elasticity Imag	2017
Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Clinical therapeutics, 2017, Volume: 39, Issue:3 Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents;	2017
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. International journal of obesity (2005), 2010, Volume: 34, Issue:8 Topics: Adult; Body Mass Index; Diet; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Non	2010
Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism: clinical and experimental, 2011, Volume: 60, Issue:9 Topics: Adult; Aged; Arteries; Blood Flow Velocity; Blood Glucose; Fatty Liver; Female; Humans; Hypoglycemic	2011
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 2011, Apr-27, Volume: 305, Issue:16 Topics: Adolescent; Alanine Transaminase; Antioxidants; Child; Double-Blind Method; Fatty Liver; Female; Hum	2011
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:5 Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination;	2011
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia, 2011, Volume: 54, Issue:12 Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy,	2011
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. European journal of endocrinology, 2012, Volume: 166, Issue:3 Topics: Adult; alpha-2-HS-Glycoprotein; Biomarkers; Cross-Sectional Studies; Dose-Response Relationship, Dru	2012
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovascular diabetology, 2012, Jun-07, Volume: 11 Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; Down-Regulation; Fatty Liver; Female; Hemodynam	2012
Metformin superior to low‑fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis. Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122 Suppl 1 Topics: Adult; Diet, Fat-Restricted; Fatty Liver; Female; Humans; Male; Metformin; Middle Aged; Non-alcoholi	2012
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Hepato-gastroenterology, 2012, Volume: 59, Issue:119 Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases;	2012

metformin and Fatty Liver, Nonalcoholic